Arbutus Biopharma Corporation
ABUS
$2.98
$0.093.11%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.40% | 11.95% | -14.44% | -20.45% | -3.64% |
| Total Depreciation and Amortization | 6.29% | 16.94% | 7.58% | -10.70% | -15.23% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.43% | -84.48% | 2,060.29% | 6.02% | -16.83% |
| Change in Net Operating Assets | 76.82% | -57.68% | -141.57% | 47.41% | -135.50% |
| Cash from Operations | 29.32% | -1.78% | -16.54% | 3.62% | -232.41% |
| Capital Expenditure | 18.80% | 100.00% | 64.84% | -305.19% | -56.00% |
| Sale of Property, Plant, and Equipment | -- | 100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.81% | 73.15% | 176.51% | 116.86% | 128.00% |
| Cash from Investing | -29.88% | 75.25% | 175.91% | 110.42% | 127.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.66% | -65.65% | -81.59% | 4,096.46% | 77.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 19.66% | -65.65% | -81.59% | 4,096.46% | 77.77% |
| Foreign Exchange rate Adjustments | -425.00% | 450.00% | 144.44% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.63% | 29.27% | 58.54% | 60.67% | 135.05% |
